Why These Three Stocks Are on Sale: APP, CNC, and MOH
After mobile advertising supplier AppLovin (APP) traded to as high as $525.15, the stock lost 12.22% on Wednesday. APP stock closed at $331, erasing the post-earnings rally.A short report from Fuzzy Panda and Culper created panic selling on AppLovin. Both firms hold a short position in the firm. The CEO posted a blog post to respond to the “nefarious short-sellers (who) are making false and misleading claims.” The CEO said that AppLovin has sophisticated AI models to enhance advertising for its partners.Centene (CNC) closed at $56.90, down by 7.22%. President Trump signed an executive order late Tuesday. He directed federal agencies to require insurers and providers to offer more transparent healthcare prices.Centene, UnitedHealth (UNH), Humana (HUM), CVS Health (CVS), Cigna (CI), Alignment Healthcare (ALHC), and Elevance Health (ELV) fell on Wednesday. Watch out for these stocks staging a rebound as fears subside. Molina Healthcare (MOH) is a notable decliner. The stock offers strong growth and profitability but trades at a premium.RisksThe House passed a budget proposal that will result in billions of dollars in Medicaid cuts. The Energy and Commerce Committee has responsibilities that include Medicaid and Medicare. It needs to find around $880 billion in cost cuts.Your TakeawayBet on the Committee minimizing cuts to Medicaid. It may find cost savings in other areas.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


